(BLCO) Bausch + Lomb - Overview
Sector: Healthcare | Industry: Medical Instruments & Supplies | Exchange: NYSE (USA) | Market Cap: 5.676m USD | Total Return: 33.7% in 12m
Avg Turnover: 7.34M
EPS Trend: -82.7%
Qual. Beats: 1
Rev. Trend: 98.0%
Qual. Beats: 0
Warnings
High Debt/EBITDA (6.6) with thin interest coverage (0.7)
Interest Coverage Ratio 0.7 is critical
Altman Z'' 0.05 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
No distinct edge detected
Bausch + Lomb Corporation is a global eye health provider operating through three integrated segments: Vision Care, Pharmaceuticals, and Surgical. The company manufactures a comprehensive portfolio ranging from daily disposable contact lenses and over-the-counter eye drops to specialized surgical equipment and intraocular lenses for cataract and retinal procedures.
Operating within the Health Care Supplies industry, the company utilizes a business model that combines recurring consumer revenue from contact lenses and vitamins with high-margin clinical sales of prescription pharmaceuticals and surgical hardware. The eye health sector is characterized by high barriers to entry due to stringent regulatory requirements for medical devices and ophthalmic drugs.
Headquartered in Canada and operating as a subsidiary of Bausch Health Companies Inc., the firm distributes its products internationally through direct sales forces and third-party distributors. Investors may find it useful to examine ValueRay for further data on the companys market position. Founded in 1853, Bausch + Lomb remains a primary supplier for both corrective vision needs and complex ophthalmic surgeries.
- High debt leverage and parent company Bausch Health litigation impact equity valuation
- Growth in Miebo and Xiidra prescriptions drives ophthalmic pharmaceutical revenue expansion
- Aging global demographics increase long-term demand for cataract surgery and surgical consumables
- Rising contact lens adoption in emerging markets fuels Vision Care segment growth
- Potential divestiture or full spinoff from Bausch Health remains a primary catalyst
| Net Income: -219.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.00 > 0.02 and ΔFCF/TA 1.28 > 1.0 |
| NWC/Revenue: 18.36% < 20% (prev 20.05%; Δ -1.69% < -1%) |
| CFO/TA 0.02 > 3% & CFO 340.4m > Net Income -219.0m |
| Net Debt (4.80b) to EBITDA (724.0m): 6.63 < 3 |
| Current Ratio: 1.53 > 1.5 & < 3 |
| Outstanding Shares: last quarter (355.2m) vs 12m ago 0.68% < -2% |
| Gross Margin: 55.86% > 18% (prev 0.59%; Δ 5.53k% > 0.5%) |
| Asset Turnover: 38.28% > 50% (prev 35.96%; Δ 2.32% > 0%) |
| Interest Coverage Ratio: 0.71 > 6 (EBITDA TTM 724.0m / Interest Expense TTM 434.0m) |
| A: 0.07 (Total Current Assets 2.78b - Total Current Liabilities 1.82b) / Total Assets 13.8b |
| B: -0.07 (Retained Earnings -1.00b / Total Assets 13.8b) |
| C: 0.02 (EBIT TTM 308.0m / Avg Total Assets 13.6b) |
| D: -0.30 (Book Value of Equity -2.20b / Total Liabilities 7.33b) |
| Altman-Z'' = 0.05 = B |
| DSRI: 1.02 (Receivables 1.11b/1.01b, Revenue 5.21b/4.83b) |
| GMI: 1.05 (GM 55.86% / 58.65%) |
| AQI: 0.98 (AQ_t 0.67 / AQ_t-1 0.68) |
| SGI: 1.08 (Revenue 5.21b / 4.83b) |
| TATA: -0.04 (NI -219.0m - CFO 340.4m) / TA 13.8b) |
| Beneish M = -2.96 (Cap -4..+1) = A |
As of May 27, 2026, the stock is trading at USD 15.78 with a total of 215,306 shares traded.
Over the past week, the price has changed by -2.05%,
over one month by -0.63%,
over three months by -14.66% and
over the past year by +33.73%.
Bausch + Lomb has received a consensus analysts rating of 3.53. Therefore, it is recommended to hold BLCO.
- StrongBuy: 3
- Buy: 3
- Hold: 8
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 18 | 14.3% |
P/E Forward = 14.5349
P/S = 1.0899
P/B = 0.8898
P/EG = 0.8878
Revenue TTM = 5.21b USD
EBIT TTM = 308.0m USD
EBITDA TTM = 724.0m USD
Long Term Debt = 5.03b USD (from longTermDebt, last quarter)
Short Term Debt = 39.0m USD (from shortTermDebt, last quarter)
Debt = 5.07b USD (corrected: LT Debt 5.03b + ST Debt 39.0m)
Net Debt = 4.80b USD (calculated: Debt 5.07b - CCE 268.0m)
Enterprise Value = 10.5b USD (5.68b + Debt 5.07b - CCE 268.0m)
Interest Coverage Ratio = 0.71 (Ebit TTM 308.0m / Interest Expense TTM 434.0m)
EV/FCF = 1000.0x (Enterprise Value 10.5b / FCF TTM 4.33m)
FCF Yield = 0.04% (FCF TTM 4.33m / Enterprise Value 10.5b)
FCF Margin = 0.08% (FCF TTM 4.33m / Revenue TTM 5.21b)
Net Margin = -4.21% (Net Income TTM -219.0m / Revenue TTM 5.21b)
Gross Margin = 55.86% ((Revenue TTM 5.21b - Cost of Revenue TTM 2.30b) / Revenue TTM)
Gross Margin QoQ = 56.59% (prev 58.08%)
Tobins Q-Ratio = 0.76 (Enterprise Value 10.5b / Total Assets 13.8b)
Interest Expense / Debt = 8.56% (Interest Expense 434.0m / Debt 5.07b)
Taxrate = 21.0% (US default 21%)
NOPAT = 243.3m (EBIT 308.0m * (1 - 21.00%))
Current Ratio = 1.53 (Total Current Assets 2.78b / Total Current Liabilities 1.82b)
Debt / Equity = 0.79 (Debt 5.07b / totalStockholderEquity, last quarter 6.38b)
Debt / EBITDA = 6.63 (Net Debt 4.80b / EBITDA 724.0m)
Debt / FCF = 1.11k (out of range, set to none) (Net Debt 4.80b / FCF TTM 4.33m)
Total Stockholder Equity = 6.42b (last 4 quarters mean from totalStockholderEquity)
RoA = -1.61% (Net Income -219.0m / Total Assets 13.8b)
RoE = -2.95% (Net Income TTM -219.0m / Total Stockholder Equity 7.43b)
RoCE = 2.47% (EBIT 308.0m / Capital Employed (Equity 7.43b + L.T.Debt 5.03b))
RoIC = 2.04% (NOPAT 243.3m / Invested Capital 11.9b)
WACC = 8.14% (E(5.68b)/V(10.7b) * Re(9.37%) + D(5.07b)/V(10.7b) * Rd(8.56%) * (1-Tc(0.21)))
Discount Rate = 9.37% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 85.40 | Cagr: 0.56%
[DCF] Terminal Value 75.44% ; FCFF base≈4.33m ; Y1≈4.35m ; Y5≈4.60m
[DCF] Fair Price = N/A (negative equity: EV 71.6m - Net Debt 4.80b = -4.73b; debt exceeds intrinsic value)
EPS Correlation: -82.72 | EPS CAGR: -36.12% | SUE: 0.87 | # QB: 1
Revenue Correlation: 97.95 | Revenue CAGR: 11.17% | SUE: 0.13 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.16 | Chg30d=+2.77% | Revisions=-8% | Analysts=14
EPS next Quarter (2026-09-30): EPS=0.22 | Chg30d=-4.93% | Revisions=-38% | Analysts=14
EPS current Year (2026-12-31): EPS=0.80 | Chg30d=+2.68% | Revisions=+38% | GrowthEPS=+56.2% | GrowthRev=+7.2%
EPS next Year (2027-12-31): EPS=1.06 | Chg30d=+0.84% | Revisions=+7% | GrowthEPS=+33.4% | GrowthRev=+5.7%
[Analyst] Revisions Ratio: -38%